Kornimate/medical-research-clean huggingface dataset:
bnp and vascular surgery

Conditions: General Anesthesia; Vascular Surgery; Abdominal Aortic Aneurysm; Natriuretic Peptide, Brain; Mets; Preoperative Period; Postoperative Period

Summary: background and rationale of the study: patients undergoing non-cardiac major surgery show a perioperative cardiac risk and postoperative complications, that can be stratified based on parameters linked to patient's conditions and to surgery types. an accurate identification of this risk could offer numerous advantages for these patients, who's 30-day mortality is around 2%. the identification of the correct risk could lead to a better pre- and postoperative management, that could guarantee a better surgery outcome and a faster postoperative recovery. to this day there is no perfect method to correctly estimate this risk. various studies show that high bnp levels are linked to cardiac events at 30 and 180 days. further investigations identify different groups, at low, intermediate and high risk, based on bnp levels. bnp is released by ventricular myocytes in response to a wall distress, due to an increased volume, pressure or myocardial ischemia. so bnp plasma levels could be used as a prognostic and diagnostic marker, improving the cardiac risk stratification in patients undergoing surgery and a much more precise management. this study is determined to do an evaluation of the correlations between pre- and postoperative bnp levels and the incidence of cardiac events in patients undergoing major vascular surgery.

patient's informed consent signature for adhesion at the study will be initially requested. with their acceptance, parameters will be recorded anonymously in the case report form, identified by their initials and a numeric code, until hospital discharge. the parameters analyzed will be related to: * preoperative evaluation: anamnesis, health general conditions, mets, preoperative monitoring, in particularly bnp basal levels; * intraoperative evaluation: intraoperative monitoring; * postoperative evaluation: bnp and ctni levels at 24 and 48 hours, and about pulmonary, cardiovascular, neurological and surgical postoperative complications, based on the medical record. the data will be transferred on excel worksheet, utilized for descriptive analysis related at every variable.

Eligibility criteria:
inclusion criteria: * ability to provide an informed consent * age \>18 years old * elective abdominal aortic aneurysm surgery exclusion criteria: * emergency surgery * age ˂ 18 years old * creatinine \>2mg/dl * diseases of ascending aorta, aortic arch or thoracic aorta * chronic atrial fibrillation * patient refusal to provide informed consent
effects of panax ginseng and salvia miltiorrhiza supplementation on vascular function

Conditions: Healthy

Summary: the purpose of is to determine the preventive effects of chinese herb supplement with panax ginseng and salvia miltiorrhiza prior to eccentric resistance exercise on arterial stiffness and vascular reactivity by using a double-blind randomized control design and to examine the effects of a 12-week progressive eccentric resistance exercise training on arterial elasticity and vascular reactivity, and whether a long-term supplementation would ameliorate arterial stiffening effects elicited by exercise-induced inflammation and improve endothelial function.


Eligibility criteria:
inclusion criteria: -healthy sedentary adults exclusion criteria: * obesity (bmi \>30 kg/m2) * smoking within past six months * hypertension (high blood pressure \>140/90 mmhg) * personal history of diabetes (fasting blood glucose \>126 mg/dl), heart disease, or other cardiovascular problems * orthopedic injury that may prevent him or her from completing the exercise * the use of over-the-counter supplements or vitamins
prevalence of echocardioghraphic and ecg changes in patients with acute pancreatitis and its impact on outcome.

Conditions: Acute Pancreatitis

Summary: cardiovascular system involvement with acute pancreatitis has been described before in the form of ecg changes and echocardiographic findings. however the correlation between these changes and the outcome of acute pancreatitis has not been and whether they can be used to predict mortality in these patients has been controversial.in the current study our aim is to detect echocardioghraphic and ecg changes in acute pancreatitis and investigate the significance of these changes on prognosis.

acute pancreatitis is a relatively common disease with significant morbidity and mortality. about 75% of pancreatitis is caused by gallstones or alcohol. the atlanta classification of acute pancreatitis has been used to differentiate between severe and mild cases of acute pancreatitis. according to this classification, patients are diagnosed with severe acute pancreatitis if they show evidence of organ failure, local complications (eg, necrosis, abscess, pseudocyst), ranson score of 3 or higher or apache score of 8 or higher. severe acute pancreatitis has a wide range of affection on nearly all body systems with various degrees of affection than affect both the clinical picture and the prognosis of the disease. the cardiovascular system involvement has been described before ,in the form of ecg changes (sinus tachycardia, arrhythmias, conduction abnormalities.. ) and echocardiographic findings (diastolic,systolic or combined dysfunction, wall motion abnormalities, pericardial effusion..). however the correlation between these changes and the outcome of acute pancreatitis has not been and whether they can be used to predict mortality in these patients has been controversial.in the current study our aim is to detect echocardioghraphic and ecg changes in acute pancreatitis and investigate the significance of these changes on prognosis.

Eligibility criteria:
inclusion criteria: * all patients with acute pancreatitis aged more than 18 yrs admitted to al-raghy icu of all etiologies exclusion criteria: * patients less that 18 years * patients above 80 years * patients with known cardiac disease * patients with pre-existing diabetes, chronic renal failure or malignancy. * patients with underlying chronic pancreatitis
to demonstrate the relative bioequivalency comparing geneva's 10 mg glipizide tablets to roerig's 10 mg glucotrol tablets

Conditions: Type 2 Diabetes

Summary: to demonstrate the relative bioequivalency comparing geneva's 10 mg glipizide tablets to roerig's 10 mg glucotrol tablets.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
rotem® sigma performance evaluation - method comparison with predicate device and reference intervals

Conditions: Blood Coagulation Disorders

Summary: rotem® sigma is a new thromboelastometric coagulation analysis system. the new system is fully automated allowing for a simple and safe operation compared to its predecessor model rotem® delta. method comparison of rotem® sigma with predecessor model rotem® delta) - confirmation of equality. confirmation of reference intervals of the rotem® systems.

the main innovation of rotem® sigma is the development of a sample handler and a cartridge allowing for a of full automated test operation. as in rotem® delta four different tests can be run simultaneously on the four channels of the analyser. whereas the tests in rotem® delta are performed manually by pipetting a blood sample and liquid system reagents, in rotem® sigma the reagents are contained in freeze dried pellet form in a cartridge. test operation is performed by inserting a cartridge and attaching a blood sample to the analyser. the five available rotem® tests intem, extem, fibtem, aptem, and heptem are contained in different combinations in two cartridge configurations: * cartridge type 1 including intem, extem, fibtem, aptem * cartridge type 2 including intem, extem, fibtem, heptem aim of the study is the performance evaluation of the new rotem® sigma coagulation analyzer in comparison to the current rotem® delta thromboelastometry system. as a valid method comparison requires test results that cover the whole measurement range of the test system it is also necessary to include acute bleeding and emergency patients in the study. only the inclusion of acute bleeding and emergency patients will produce strong pathologic test results allowing for a valid evaluation of the test system.

Eligibility criteria:
inclusion criteria: patients: * age ≥ 18 years * informed written consent * patients with an acute bleeding during surgery * or: trauma patients with acute bleeding * or: hypercoagulable (above normal fibrinogen) patients at the icu healthy volunteers: * adult healthy individuals (≥ 18 years) * written informed consent exclusion criteria: patients: • none healthy volunteers: * any indications of alcohol or illegal drug abuse * any chronic disease with possible effect on the coagulation (liver disease, coronary heart disease) * any acute illness within the last 14 days * any hemostasis associated disease (myocardial infarction, thrombosis , stroke etc.) within the last year * intake of any coagulation affecting medication (aspirin, pain-killers, anti-rheumatic drugs, marcumar, platelet inhibitors) within the last 14 days * females only: known pregnancy * females only: breast feeding * any indication for any hemostasis disorder as interrogated by a specific history of bleeding tendencies
outpatient treatment of severe and enduring anorexia nervosa

Conditions: Anorexia

Summary: approximately 20-30 % of individuals with the eating disorder anorexia nervosa develop an enduring form of the illness. in this study a new treatment for patients with severe and enduring anorexia nervosa was described. the treatment is flexible and aims at enhancing quality of life. the participants consisted of all referrals resulting in an assessment or treatment period at the unit between may 2017 and may 2022. the study was a registry study. information regarding patient characteristics, treatment goals, and the course of treatment was gathered from medical records.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * a referral resulting in an assessment or treatment period at the unit for patients with severe and enduring anorexia nervosa at the hus helsinki university hospital between may 2017 and may 2022.

Keywords: anorexia nervosa severe and enduring anorexia nervosa treatment
proof of concept study of bms-823778 to assess the effects on atherosclerosis

Conditions: Atherosclerotic Cardiovascular Disease

Summary: the purpose of the study is to assess the effect of bms-823778 on reducing atherosclerotic plaque inflammation


Eligibility criteria:
inclusion criteria: * documented atherosclerotic cardiovascular disease or at high risk of cardiovascular event * on stable statin dose * clinically stable at time of screening and randomization exclusion criteria: * women of child bearing potential * medical conditions that would impact the absorption of the study drug
pilot study of patient's adherence to tykerb™/tyverb™ + capecitabine in metastatic breast cancer

Conditions: Cancer

Summary: this is a 6-week, single arm, pilot study to test the study procedure, educational materials, and measurement instruments for the educational intervention in her2 overexpressing metastatic or advanced breast cancer patients

approximately 60 subjects with her2+ metastatic or advanced breast cancer who meet the inclusion/exclusion criteria will be enrolled into the study. all subjects will receive education intervention for 6 weeks including education on day 0, follow-up phone calls on day 1 and day 7, reminder phone calls before week 3 and 6 visit and telephone hot line number.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent; 2. female outpatient aged 18 years or older; 3. subjects must be about to begin their initial treatment with lapatinib + capecitabine for her2+ metastatic or advanced breast cancer according to physician's clinical judgement as per local prescribing information 4. subjects must be literate, be able to read, understand and write local language. exclusion criteria: 1. women who is participating in any other interventional clinical trials concurrently; 2. women who is already taking or had taken lapatinib + capecitabine regimen prior to the enrollment; 3. primary lesions that are not of breast origin.
migraine induction properties of pacap-38 after eptinezumab in migraine without aura patients.

Conditions: Migraine

Summary: to investigate whether administration of calcitonin gene-related peptide (cgrp) binding monoclonal antibodies eptinezumab prevents pituitary adenylate cyclase-activating polypeptide-38 (pacap-38) induced migraine attacks in migraine without aura patients.

the aim of the present study is to investigate whether - cgrp binding monoclonal antibodies eptinezumab prevents pacap-38 induced migraine attacks in migraine without aura patients. clinical and basic research have established calcitonin gene-related peptide (cgrp) as central molecule in migraine pathophysiology, yet existing cgrp antagonizing therapies such as the cgrp and cgrp receptor binding monoclonal antibodies are only effective in 50-60% of migraine patients. pacap-38 and cgrp colocalize in the trigeminovascular system, and both activate adenylate cyclase upon receptor binding which causes increased formation of cyclic amp (camp). it is unknown if cgrp and pacap-38 signaling pathways differ sufficiently for pacap-38 to be an alternative treatment target to cgrp. whether administration of cgrp binding monoclonal antibodies eptinezumab prevents pacap-38 induced migraine attacks in migraine without aura patients is yet to be investigated.

Eligibility criteria:
inclusion criteria: * healthy volunteers of both sexes. * 18-60 years. * 50-100 kg. * women of childbearing potential must use adequate contraception * history of migraine without aura for ≥ 12 months according to the international classification of headache disorders 3rd edition (ichd-3) criteria. * no migraine preventive treatment. exclusion criteria: * a history of serious somatic disease * \> 50 years of age at migraine onset. * history of any other primary headaches disorder (except ≤ 5 monthly days with tension- type headache). * daily intake of any medication except contraceptives

Keywords: headache vascular effect
a multilevel intervention to improve uptake of gastrointestinal cancer screening: a cluster randomized clinical trial

Conditions: Screening Compliance

Summary: this study is a cluster randomized controlled trial aimed at evaluating the effectiveness of a multi-level intervention strategy in improving adherence to gastrointestinal cancer screening. communities will be randomly assigned as the unit of randomization to either intervention or control group. the study population includes community residents aged 50-74 years. communities in the intervention group will receive multi-level interventions including health education, patient navigation services, and appointment assistance, while communities in the control group will maintain routine screening management. all participants will be followed up for 90 days to track their endoscopy appointment and completion rates. the main research question is: can community-based multi-level intervention effectively improve adherence to gastrointestinal cancer screening among community residents?


Eligibility criteria:
inclusion criteria: * high-risk individuals of gastrointestinal cancer in 45-74 years old exclusion criteria: * unable to give consent * history of cancer * severe cardiac, pulmonary, brain, or renal dysfunction or any other serious disease * psychiatric illness * pregnancy
early multimodal therapy and mechanical ventilation

Conditions: Critical Care; Critical Illness

Summary: to assess the association between early multimodal therapy and the duration of invasive mechanical ventilation in the intensive care unit at fundación santa fe de bogotá.

this study compares the impact of early multimodal therapy on mechanical ventilation duration in icu patients. it is an open-label, randomized controlled clinical trial. patients will be assigned to either early multimodal therapy or standard therapy (control) in a 1:1 ratio. blinding is not possible due to the study design. the analysis will follow an intention-to-treat approach. the hypothesis is that early multimodal therapy reduces mechanical ventilation duration

Eligibility criteria:
inclusion criteria: the inclusion criteria are as follows: patients hospitalized in the adult intensive care unit of the fundación santa fe de bogotá. requirement of invasive mechanical ventilation through an endotracheal tube for a period exceeding 72 hours with an expected continuation of at least 24 hours. barthel index equal to or greater than 70 exclusion criteria: exclusion criteria: * patients requiring invasive mechanical ventilation through a tracheostomy tube or nasotracheal tube. * patients who have undergone any type of head and neck surgery. * cardiac arrest. * airway burn. * burns with an extent greater than 50% of the body surface area. * patients with chronic obstructive pulmonary disease. * patients referred from another institution. * demyelinating or neuromuscular junction diseases. * patients requiring neuromuscular blockade. * patients with a life expectancy of less than 180 days. * patients deemed by medical criteria not to benefit from multimodal treatment. * patients not entering the icu for the first time. * patients participating in other clinical rehabilitation trials
methylation, microbiome, nutritional status, and development of stunted children

Conditions: Stunting; Development, Child; DNA Methylation; Epigenetics; Nutrition

Summary: the investigators will conduct a case-control study among under-two children in lombok timur, west nusa tenggara, indonesia. the power required to detect changes in epigenetic markers may not be sufficient in the cohort study. therefore, specific case-control design of stunted vs non-stunted children will provide the required power to detect potential epigenetic markers which will be further investigated through targeted sequencing of the cohort study. a total of 150 stunted children will be recruited and then it will be matched with 150 non-stunted children with the same sex. the assessments for these study subjects will include: 1) the genetic and epigenetic profile of the children, gut microbiota and nutritional status (physical component), 2) food security, water, sanitation and hygiene (wash) and infant and young child feeding (iycf) practices (home-food component), 3) children's psychosocial care and cognitive outcome (cognition component).

this study is part of action against stunting hub, an observational cohort study aimed to build evidence based on exploring the drivers of stunting from different perspectives and understand the impact of different interventions across three countries: india, indonesia and senegal. this study is intended to give the overview of stunting and its determinants among under-two children growing up during period of covid-19 pandemic in lombok timur, nusa tenggara barat, indonesia. because, the power required to detect changes in epigenetic markers may not be sufficient in the cohort study, this specific case-control design of stunted vs non-stunted children will also provide the required power to detect potential epigenetic markers which will be further investigated through targeted sequencing of the cohort study. the results of this initial study are projected to support further study, especially the observational cohort study, in determining the best suited indicators to prove the interaction and/or causal mechanisms of stunting.

Eligibility criteria:
inclusion criteria: * aged 18.0 - 23.9 months * without serious illnesses * the mother delivered the children between 18-40 years of age * has sasak ethnicity, (5) recumbent length \ -1sd (for non- stunted group) from the who child growth standards median for their age and sex at the recruitment. exclusion criteria: * twin birth * congenital malformation * consanguinity

Keywords: epigenetics signature case-control under-two-year-old children
colposcopy and high resolution anoscopy in screening for anal dysplasia in patients with cervical, vaginal, or vulvar dysplasia or cancer

Conditions: Cervical Intraepithelial Neoplasia Grade 1; Cervical Intraepithelial Neoplasia Grade 2; Cervical Intraepithelial Neoplasia Grade 3; Recurrent Cervical Cancer; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Stage 0 Cervical Cancer; Stage 0 Vaginal Cancer; Stage 0 Vulvar Cancer; Stage I Vaginal Cancer; Stage I Vulvar Cancer; Stage IA Cervical Cancer; Stage IB Cervical Cancer; Stage II Vaginal Cancer; Stage II Vulvar Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IV Vulvar Cancer; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer

Summary: this clinical trial studies colposcopy and high resolution anoscopy in screening for anal dysplasia in patients with cervical, vaginal, or vulvar dysplasia or cancer. screening may help doctors find cancer cells early and plan better treatment for cancer

objectives: i. to evaluate the risk of anal dysplasia in women with cervical or vulvar dysplasia. outline: patients undergo colposcopy and cervical papanicolaou test with human papillomavirus (hpv) test followed by anal papanicolaou test and high resolution anoscopy. patients with dysplastic anal lesions undergo repeat anoscopy at 3, 9, 15, and 24 months. patients with normal anoscopy are followed up at 1 and 2 years.

Eligibility criteria:
inclusion criteria: * histological confirmation of cervical, vaginal or vulvar intraepithelial neoplasia or cancer are included * individuals treated with prior radiation therapy and/or chemotherapy are allowed * women with high-grade dysplasia (carcinoma in situ) are eligible, regardless of their dysplasia free interval * hiv-positive (human immunodeficiency virus) and hiv-negative women will be enrolled; hiv testing will not be performed as part of the study exclusion criteria: * women who are not able to consent are excluded
a clinical trial to evaluate efficacy and safety of levophencynonate hydrochloride in patient with vertigo

Conditions: Vertigo

Summary: a multicenter, double-blind, placebo controlled, phase ⅱa clinical trial to enroll 120 patients with vertigo caused by posterior circulation infarction during 7 days, then to evaluate the efficacy of different dose of levophencynonate hydrochloric, and provide the effective dosage for phase iib clinical study, to study the safety of levophencynonate hydrochloric.

this study will conduct in 15 sites to enrolled 120 patients with vertigo under 7 days treatment and 7 days follow-up. the study includes three arms: high dose, low dose and placebo control.to observe the efficacy by change of vertigo severity and duration,and safety by vital sign,adverse event,etc.

Eligibility criteria:
inclusion criteria: 1. at the age more than 18 years old male or female; 2. patients with vertigo caused by posterior circulation infarction. 3. patients diagnosed posterior circulation infarction based on the criteria of posterior circulation ischemia of america; 4. meet the diagnose criteria of vertigo: visual motion (external vertigo), or rotation, swing, lift and tilt sensation (internal vertigo); 5. ability to sign the statements of informed consent; exclusion criteria: 1. female patients having pregnant, lactating or birth plan recently; 2. non-posterior circulation infarction patients; 3. vertigo caused by any other diseases; 4. long-term alcohol abuse, or drug abuse; 5. been in critical condition, difficult to make a precise evaluation of efficacy and safety of new drugs; 6. history of allergies on levophencynonate hydrochloric or these compositions; 7. participation in another clinical trial in three months; 8. investigator thought that should be excluded due to other reason;